Pathogenetic role of glomerular CXCL13 expression in lupus nephritis

Clinical and Experimental Immunology

Volumn 178, Issue 1, 2014, Pages 20-27

  Worthmann, K ^a   Gueler, F ^a   Von Vietinghoff, S ^a   Davalos Mi, A ^a   Wiehler, F ^a   Davidson, A ^a   Witte, T ^b   Haller, H ^a   Schiffer, M ^a   Falk, C S ^c   Schiffer, L ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Integrated Research and Treatment Center Transplantation   (Germany)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Chemokines; CXCL13; Podocytes; Proinflammatory signaling; SLE nephritis

Indexed keywords

CXCL13 CHEMOKINE; CHEMOKINE RECEPTOR CXCR5; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DENDRITIC CELL; FLUORESCENCE ACTIVATED CELL SORTING; GLOMERULAR FILTRATION BARRIER; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NEUTROPHIL; NONHUMAN; PODOCYTE; RESPIRATORY BURST; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GLOMERULUS; GRANULOCYTE; METABOLISM; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; CELLS, CULTURED; CHEMOKINE CXCL13; CYTOKINES; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS; GRANULOCYTES; HUMANS; KIDNEY GLOMERULUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; NEUTROPHILS; PODOCYTES; RECEPTORS, CXCR5;

EID: 84908162474     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12380     Document Type: Article

References (45)

1. Chung AC, Lan HY. Chemokines in renal injury. J Am Soc Nephrol 2011; 22:802-9.
2. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91:295-8.
3. Sener AG, Afsar I. Infection and autoimmune disease. Rheumatol Int 2012; 32:3331-8.
4. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345:340-50.
5. Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998; 391:799-803.
6. Luther SA, Ansel KM, Cyster JG. Overlapping roles of CXCL13, interleukin 7 receptor alpha, and CCR7 ligands in lymph node development. J Exp Med 2003; 197:1191-8.
7. Ansel KM, Ngo VN, Hyman PL et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406:309-14.
8. Ishikawa S. [Aberrant high expression of B lymphocyte chemoattractant (BLC/CXCL13) in a murine model for SLE]. Tanpakushitsu Kakusan Koso 2002; 47:2369-74.
9. Schiffer L, Sinha J, Wang X et al. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003; 171:489-97.
10. Schiffer L, Bethunaickan R, Ramanujam M et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008; 180:1938-47.
11. Schiffer L, Kumpers P, Davalos-Misslitz AM et al. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant 2009; 24:3708-12.
12. Schiffer L, Kielstein JT, Haubitz M et al. Elevation of serum CXCL13 in SLE as well as in sepsis. Lupus 2011; 20:507-11.
13. Ezzat M, El-Gammasy T, Shaheen K, Shokr E. Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement. Lupus 2011; 20:845-54.
14. Lee HT, Shiao YM, Wu TH et al. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 2010; 37:45-52.
15. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol 2010; 30:45-52.
16. Sprangers B, Monahan M, Appel GB. Diagnosis and treatment of lupus nephritis flares - an update. Nat Rev Nephrol 2012; 8:709-17.
17. Ishikawa S, Sato T, Abe M et al. Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med 2001; 193:1393-402.
18. Ishikawa S, Nagai S, Sato T et al. Increased circulating CD11b+CD11c+ dendritic cells (DC) in aged BWF1 mice which can be matured by TNF-alpha into BLC/CXCL13-producing DC. Eur J Immunol 2002; 32:1881-7.
19. Banas MC, Banas B, Hudkins KL et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 2008; 19:704-13.
20. Huber TB, Reinhardt HC, Exner M et al. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002; 168:6244-52.
21. Brahler S, Ising C, Hagmann H et al. Intrinsic proinflammatory signaling in podocytes contributes to podocyte damage and prolonged proteinuria. Am J Physiol Renal Physiol 2012; 303:F1473-F1485.
22. Saleem MA, O'Hare MJ, Reiser J et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 2002; 13:630-8.
23. von Vietinghoff S, Choi M, Rolle S, Luft FC, Kettritz R. Febrile temperatures control antineutrophil cytoplasmic autoantibodyinduced neutrophil activation via inhibition of phosphatidylinositol 3-kinase/Akt. Arthritis Rheum 2007; 56:3149-58.
24. Yu CC, Fornoni A, Weins A et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369:2416-23.
25. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophilactivating properties of the melanoma growth-stimulatory activity. J Exp Med 1990; 171:1797-802.
26. Schumacher C, Clark-Lewis I, Baggiolini M, Moser B. High-and low-affinity binding of GRO alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils. Proc Natl Acad Sci USA 1992; 89:10542-6.
27. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cellderived factor 1 (SDF-1). J Exp Med 1996; 184:1101-9.
28. Welford AF, Biziato D, Coffelt SB et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vasculardisrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011; 121:1969-73.
29. Xu J, Li Z, Xu P, Yang Z. Protective effects of leukemia inhibitory factor against oxidative stress during high glucose-induced apoptosis in podocytes. Cell Stress Chaperones 2012; 17:485-93.
30. Besse-Eschmann V, Le HM, Endlich N, Endlich K. Alteration of podocytes in a murine model of crescentic glomerulonephritis. Histochem Cell Biol 2004; 122:139-49.
31. Welsh GI, Saleem MA. The podocyte cytoskeleton - key to a functioning glomerulus in health and disease. Nat Rev Nephrol 2012; 8:14-21.
32. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases:is the podocyte the culprit? Kidney Int 1998; 54:687-97.
33. Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Genet 2000; 24:333-5.
34. Henry J, Miller MM, Pontarotti P. Structure and evolution of the extended B7 family. Immunol Today 1999; 20:285-8.
35. Reiser J, von Gersdorff G, Loos M et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113:1390-7.
36. Murtas C, Bruschi M, Candiano G et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 2012; 7:1394-400.
37. Debiec H, Hanoy M, Francois A et al. Recurrent membranous nephropathy in an allograft caused by IgG3kappa targeting the PLA2 receptor. J Am Soc Nephrol 2012; 23:1949-54.
38. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 2007; 1773:1213-26.
39. El-Haibi CP, Singh R, Gupta P et al. Antibody microarray analysis of signaling networks regulated by Cxcl13 and Cxcr5 in prostate cancer. J Proteomics Bioinform 2012; 5:177-84.
40. Lloyd CM, Minto AW, Dorf ME et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997; 185:1371-80.
41. Bennett MR, Czech KA, Arend LJ, Witte DP, Devarajan P, Potter SS. Laser capture microdissection-microarray analysis of focal segmental glomerulosclerosis glomeruli. Nephron Exp Nephrol 2007; 107:e30-e40.
42. Sayyed SG, Hagele H, Kulkarni OP et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 2009; 52:2445-54.
43. Sanchez-Nino MD, Sanz AB, Ruiz-Andres O et al. MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple. Cytokine Growth Factor Rev 2013; 24:23-40.
44. Mebius RE. Organogenesis of lymphoid tissues. Nat Rev Immunol 2003; 3:292-303.
45. Babior BM. Oxidants from phagocytes: agents of defense and destruction. Blood 1984; 5:959-66.